Oral VEGFR-2 Tyrosine Kinase Inhibitor for Recurrent Small-Volume Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer

This study focuses on evaluating the effectiveness of an oral medication, CP-547,632, in treating small-volume epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer. These cancers often persist or recur despite initial treatment with platinum-based therapy. The study aims to help patients whose CA-125 levels, a protein indicator for these cancers, continue to rise after the first line of treatment. The potential outcomes of this research could lead to improved treatment options for those facing these challenging conditions. During the study, participants receive CP-547,632, a tyrosine kinase inhibitor that targets VEGFR-2, a protein involved in cancer growth. The primary goal is to assess whether this drug leads to a significant response in patients, as defined by predetermined response criteria. If the study's first stage does not meet these response criteria, it will not proceed to the second stage. This ensures that the study moves forward only if the drug shows promise in managing the targeted cancers.